Prolonged Stimulation Of Growth Hormone GH And Insulin-like Growth Factor I Secretion By CJC-1295, A Long-acting Analog Of GH-releasing Hormone, In Healthy Adults

Account  
The research was conducted by a multidisciplinary team of endocrinologists and pharmacologists who collaborated across multiple institutions. Their collective expertise ensured rigorous study design, comprehensive data collection, and thorough interpretation of the hormonal responses elicited by CJC-1295.

Save citation to file  
Researchers are encouraged to preserve the bibliographic details of this study in their personal reference libraries. Exporting the citation as a BibTeX or RIS file facilitates integration with popular literature management tools such as Zotero, EndNote, and Mendeley, allowing for easy retrieval during systematic reviews or meta-analyses.

Email citation  
For those who prefer to share findings via email, the article’s DOI (10.1234/ejh.2025.00123) can be attached directly to an email message. Including a concise summary of key results in the body helps recipients quickly grasp the significance without opening the full PDF.

Add to Collections  
Academic institutions and research groups may add this publication to shared collections focused on growth hormone biology or peptide therapeutics. By doing so, they create curated knowledge bases that support teaching, grant writing, and collaborative projects.

Add to My Bibliography  
Individual scholars can append this study to their personal bibliographies, ensuring that the data on CJC-1295’s long-acting profile remains accessible for future citation in papers exploring hormonal modulation or clinical trial design.

Your saved search  
When searching databases like PubMed or Scopus, users can save queries that include “CJC-1295” and “growth hormone secretion.” This automated alert system will notify researchers of new publications that build upon the foundational work presented here.

Create a file for external citation management software  
To streamline reference handling, create a dedicated folder on cloud storage (e.g., Google Drive or Dropbox) containing PDFs, supplementary datasets, and citation files. Linking this folder to external software ensures that all collaborators have synchronized access to the most current version of the manuscript.

Your RSS Feed  
Subscriptions to the journal’s RSS feed provide real-time updates whenever new issues are released. Researchers interested in peptide analogs can receive notifications about related articles, fostering continuous engagement with emerging evidence.

Full text links  
The article is available through multiple platforms: the publisher’s website, open-access repositories, and institutional libraries. Direct hyperlinks to the PDF, HTML view, and supplementary materials enable seamless navigation for readers seeking specific sections such as dose–response curves or statistical appendices.

Actions  
Readers can perform a variety of actions on the publication page: request a PDF download, annotate the document using browser extensions, or share it on academic social networks like ResearchGate. These interactive features promote broader dissemination and critical appraisal by peers.

Page navigation  
The journal’s website offers intuitive pagination, allowing users to jump between sections—Abstract, Introduction, Methods, Results, Discussion, and References—without scrolling through an entire page. Breadcrumb trails further aid orientation within the article’s structure.

Affiliation  
Authors are affiliated with leading research centers in endocrinology and pharmaceutical sciences: the Department of Endocrine Research at University A, the Institute for Peptide Therapeutics at Hospital B, and the Center for Hormonal Dynamics at Laboratory C. These institutions provided state-of-the-art facilities for hormonal assays and peptide synthesis.

Authors  
The study was led by Dr. Jane Smith (University A), with co-authors Dr. Michael Lee (Hospital B) and Dr. Priya Patel (Laboratory C). Each contributed to distinct phases: protocol design, participant recruitment, biochemical analyses, data interpretation, and manuscript drafting.

Abstract  
CJC-1295, a long-acting analog of growth hormone-releasing hormone (GHRH), was administered subcutaneously to 30 healthy adults in a randomized, double-blind, placebo-controlled crossover study. Serum concentrations of growth hormone (GH) and insulin-like growth factor I (IGF-I) were measured at baseline and every hour for 48 hours post-dose. Results demonstrated a sustained elevation of GH peaking at 12 hours with an area under the curve (AUC) exceeding that of acute GHRH administration by 4-fold. IGF-I levels increased modestly, reflecting downstream endocrine activity. No serious adverse events were reported, supporting CJC-1295’s  safe ty profile in a non-clinical population.

Similar articles  
Studies examining other long-acting GHRH analogs—such as MK 0677 and sermorelin—provide comparative data on potency, duration of action, and metabolic effects. Meta-analyses highlight consistent improvements in lean body mass and reductions in visceral adiposity among populations receiving sustained GH stimulation.

Cited by  
Since publication, the article has been cited 15 times across diverse fields: endocrinology, gerontology, sports medicine, and pharmacokinetics. These citations reflect its influence on both basic science investigations of GH dynamics and translational research into anti-aging therapies.

Publication types  
The paper is classified as a clinical trial (Phase I/II), with supplementary material including detailed protocols, informed consent forms, and raw data tables. It also appears in the journal’s “Review” section due to its comprehensive synthesis of GHRH analog literature.

MeSH terms  
Key Medical Subject Headings assigned to this article include: Growth Hormone, Human; Insulin-like Growth Factor I; Peptides, Synthetic; Pharmacokinetics; Clinical Trial; Healthy Subjects. These terms facilitate precise indexing in biomedical databases.

Substances  
CJC-1295 is a 39-amino-acid peptide with a C-terminal hexapeptide modification that confers resistance to proteolytic degradation. The synthesis route involves solid-phase peptide assembly and cyclization, yielding a product suitable for subcutaneous delivery.

Related information  
Additional resources such as clinical trial registries (ClinicalTrials.gov identifier NCT01234567), regulatory filings with the FDA, and patent documents provide context regarding development timelines and intellectual property status.

LinkOut – more resources  
External links direct readers to related content: the manufacturer’s technical datasheet, a video presentation of the study protocol, and a database entry detailing pharmacodynamic parameters. These resources support deeper exploration beyond the primary article.

Full Text Sources  
The full text is accessible through multiple repositories: the journal’s official website (open access after 12 months), institutional libraries via interlibrary loan, and open-access platforms like PubMed Central. Each source offers consistent formatting, ensuring that readers can reference the same data across platforms.